Ptc Therapeutics (PTCT) Cash from Financing Activities (2012 - 2026)

Ptc Therapeutics' Cash from Financing Activities history runs 15 years deep, the most recent figure standing at $6.4 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 31.96% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $328.1 million (up 23.93% YoY), while the FY2025 annual figure was $331.1 million, up 29.4% from the prior year.
• Cash from Financing Activities was $6.4 million for Q1 2026 at Ptc Therapeutics, down from $302.5 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $620.5 million in Q4 2023 to a low of -$140.0 million in Q3 2022.
• Historically, Cash from Financing Activities has averaged $82.8 million across 5 years, with a median of $6.4 million in 2026.
• Biggest YoY gain for Cash from Financing Activities was 6857.23% in 2022; the steepest drop was 4804.13% in 2022.
• A 5-year view of Cash from Financing Activities shows it stood at $302.9 million in 2022, then soared by 104.84% to $620.5 million in 2023, then slumped by 95.73% to $26.5 million in 2024, then jumped by 1042.78% to $302.5 million in 2025, then plunged by 97.88% to $6.4 million in 2026.
• The last three Cash from Financing Activities figures came in at $6.4 million (Q1 2026), $302.5 million (Q4 2025), and $15.2 million (Q3 2025), per Business Quant data.